Page 50 - SaxoCell Annual Report 2021
P. 50
OPTIX
The OPTIX project addresses the optimization and clinical translation of a manufacturing
process for an antibody-modified stem cell transplant (Palintra®) followed by a
prospective, multicenter, single-arm first-in-man phase I/II trial under coordination and
leadership of the Saxon company Tcell Tolerance GmbH, as well as translational
SaxoCell Projects The project involves the modification of an allogeneic hematopoietic stem cell transplant
research to further elucidate the mechanism of action.
for the treatment of hematological neoplasms, whereby the modification is intended to
reduce graft-versus-host disease while preserving the graft-versus-leukemia effect.
Project Manager: Lilly Stahl
Project Partners: Fraunhofer IZI, University Hospital Leipzig, University Hospital
Dresden, Hospital Chemnitz, Tcell Tolerance GmbH
45
